bringing energy to life

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease.

 

khondrion

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of mitochondrial dysfunction, the company is advancing its wholly owned lead drug candidate sonlicromanol for the treatment of both children and adults.  

Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders

Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary mitochondrial disease – to move into a...

Patient Perspective: A conversation with Kate Murray – CEO and President, MitoCanada

How did you first become involved with the mitochondrial disease community and MitoCanada? I joined MitoCanada at a...

Khondrion to participate in World Mitochondria Society’s Targeting Mitochondria 2022 Congress

NIJMEGEN, the Netherlands – 25 October 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and...

Patient Perspective: A conversation with Sean Murray – CEO, The Mito Foundation

How did you first become involved with the mitochondrial disease community and what led you to the Mito Foundation? I...

Interview with Tom Pulles, Chief Medical Officer at Khondrion

Tell us about your career before joining KhondrionI started my career as a physician in the Dutch Navy, 22...

Khondrion to participate in mitoNice international congress dedicated to mitochondrial medicine

NIJMEGEN, the Netherlands – 14 September 2022: Khondrion, a clinical-stage biopharmaceutical company discovering...

Patient Perspective: A conversation with Kasey Woleben – Co-founder, and Sophia Zilber – Board Member, Patient Registry Director, Cure Mito Foundation

We recently sat down with Kasey Woleben, Co-founder, and Sophia Zilber, Board Member and Patient Registry Director of...

Khondrion appoints Tom Pulles, MD, as Chief Medical Officer

NIJMEGEN, the Netherlands – 1 June 2022: Khondrion (or the “Company”), a clinical stage biopharmaceutical...

Patient Perspective: A conversation with Philip Yeske, PhD – Science & Alliance Officer, UMDF

How did you first become involved with the mitochondrial disease community and the United Mitochondrial Disease...

Patient Perspective: A conversation with Alison Maguire – Head of Research & Finance, The Lily Foundation

How did you first become involved with the mitochondrial disease community and The Lily Foundation? In 2004 I became...

working with others

At Khondrion we know that working in collaboration with others is important to accelerate the development of innovative new medicines. That is why we are pursuing cutting edge science both within our own labs and through partnerships across an extensive academic and industry network of experts and are sharing knowledge around mitochondrial disease in close collaboration with patient organizations to help develop important new medicines and treatments for patients.

“the solution is within our reach”

Since 2012 Khondrion has been progressing a pipeline with the potential to deliver transformative medicines for patients living with mitochondrial disease.

get in touch

Whether you are a researcher, job seeker, health professional, patient, potential investor or potential business partner, you can contact us using this form.